Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2015-07-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 236
- Registration Number
- NCT01017874
- Locations
- 🇹🇭
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hat Yai, Thailand
A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction
- First Posted Date
- 2009-11-18
- Last Posted Date
- 2014-02-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 4033
- Registration Number
- NCT01015287
- Locations
- 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sisli, Turkey
A Study for the Transdermal Application of Teriparatide
- Conditions
- Osteoporosis
- Interventions
- Drug: Subcutaneous TeriparatideDrug: Transdermal Teriparatide
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2012-10-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 233
- Registration Number
- NCT01011556
- Locations
- 🇷🇴
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Timisoara, Romania
A Study of IMC-A12 in Advanced Solid Tumors
- Conditions
- Tumors
- Interventions
- Biological: Cixutumumab
- First Posted Date
- 2009-11-03
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 21
- Registration Number
- NCT01007032
- Locations
- 🇯🇵
ImClone Investigational Site, Kashiwa, Japan
A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2013-12-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 256
- Registration Number
- NCT01005680
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sichuan, China
A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 336
- Registration Number
- NCT01006252
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom
Study of IMC-1121B in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Biological: IMC-1121B
- First Posted Date
- 2009-10-30
- Last Posted Date
- 2014-06-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 15
- Registration Number
- NCT01005355
- Locations
- 🇯🇵
ImClone Investigational Site, Tokyo, Japan
A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-Small Cell Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2009-10-29
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 109
- Registration Number
- NCT01004250
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Solna, Sweden
A Study of Pemetrexed and Cisplatin, in Non Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 90
- Registration Number
- NCT01000480
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain
A Study of LY2189265 in Japanese Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: LY2189265Drug: Placebo
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 145
- Registration Number
- NCT01001104
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan